| 4.66 0 (0%) | 01-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.7  |
1-year : | 6.33 |
| Resists | First : | 4.88 |
Second : | 5.42 |
| Pivot price | 4.44 |
|||
| Supports | First : | 4 | Second : | 3.32 |
| MAs | MA(5) : | 4.59 |
MA(20) : | 4.61 |
| MA(100) : | 5.19 |
MA(250) : | 4.52 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 58.5 |
D(3) : | 52.3 |
| RSI | RSI(14): 47.9 | |||
| 52-week | High : | 5.71 | Low : | 2.47 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CVAC ] has closed below upper band by 29.2%. Bollinger Bands are 191.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 30 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.67 - 4.68 | 4.68 - 4.7 |
| Low: | 4.52 - 4.54 | 4.54 - 4.56 |
| Close: | 4.62 - 4.66 | 4.66 - 4.69 |
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Tue, 13 Jan 2026
BioNTech’s CureVac Deal Put A Floor Under A Volatile Stock - Finimize
Thu, 08 Jan 2026
Does CureVac’s (CVAC) NASDAQ Exit Quietly Recast Its Risk Profile and Equity Story? - simplywall.st
Tue, 06 Jan 2026
CureVac shares to be delisted from Nasdaq following BioNTech acquisition - Investing.com
Thu, 01 Jan 2026
CureVac NV’s CVAC Stock: Volatile Gene?Therapy Bet Faces Tough Crowd On Wall Street - AD HOC NEWS
Tue, 30 Dec 2025
CureVac (NASDAQ:CVAC) Reaches New 12-Month High - What's Next? - MarketBeat
Mon, 22 Dec 2025
BioNTech SE (BNTX) Closes the Acquisition of CureVac N.V. - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 225 (M) |
| Shares Float | 181 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 10.4 (%) |
| Shares Short | 547 (K) |
| Shares Short P.Month | 959 (K) |
| EPS | 0.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.65 |
| Profit Margin | 182.1 % |
| Operating Margin | 573 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -89 % |
| Gross Profit (p.s.) | 0.29 |
| Sales Per Share | 0.31 |
| EBITDA (p.s.) | 0.86 |
| Qtrly Earnings Growth | 24 % |
| Operating Cash Flow | -120 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 6.95 |
| PEG Ratio | 0 |
| Price to Book value | 0.82 |
| Price to Sales | 14.83 |
| Price to Cash Flow | -8.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|